AMGN

Amgen

$435.64

-0.72%
Nov 20, 2026
Bobby Quantitative Model
Amgen is a global biotechnology leader that discovers, develops, manufactures, and markets human therapeutics, with a portfolio spanning hematology/oncology support (Epogen, Aranesp, Neulasta), inflammatory disease (Enbrel, Otezla), bone health (Prolia, Xgeva, Evenity), cholesterol (Repatha), and a growing rare-disease franchise (Tepezza, Krystexxa) following the 2023 Horizon Therapeutics acquisition, alongside an expanding biosimilar business. As one of the largest pure-play biotechs by revenue, Amgen occupies a mature, cash-generative incumbent position in Drug Manufacturers - General, distinguished by its biologics manufacturing scale and a pipeline now pivoting toward oncology and obesity. The current investor narrative centers on three catalysts: the Imdelltra/Imfinzi combination showing a 58% reduction in risk of death in extensive-stage small cell lung cancer (a potential practice-changing oncology win), the once-monthly obesity candidate MariTide as a differentiated entrant against Lilly and Novo Nordisk, and a sharp margin-recovery story as the company laps Horizon integration and amortization headwinds. That optimism is tempered by a cautious sell-side stance, biosimilar erosion of legacy franchises, and regulatory scrutiny around partner drugs such as Tavneos, leaving the stock in a debate between pipeline optionality and the durability of its base business.

People also watch

Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
Johnson & Johnson

Johnson & Johnson

JNJ

Analysis
AbbVie

AbbVie

ABBV

Analysis
Merck & Co.

Merck & Co.

MRK

Analysis
Gilead Sciences

Gilead Sciences

GILD

Analysis

BobbyInvestment Opinion: Should I buy AMGN Today?

Rating: Hold. Amgen is a high-quality, cash-generative biotech whose margin recovery and pipeline optionality are real, but at $465.67 the stock trades 7.3% above the $431.81 consensus target with a "hold" recommendation (mean 2.71 across 29 analysts: 11 Buy, 18 Hold, 5 Sell), meaning price has outrun the Street's published models. The core thesis is that Q3's 73.1% gross, 35.8% operating and 62.3% EBITDA margins plus $9.581 billion TTM free cash flow justify holding the position, but not adding aggressively until Q4 confirms the margin inflection without the $976 million other-income assist.

Supporting evidence is genuinely strong on fundamentals: revenue grew 8.45% YoY to $10.365 billion in Q3, gross margin expanded from 68.2% in Q1 to 73.1%, operating margin rose from 31.0% to 35.8%, and EPS more than doubled sequentially from $4.40 to $7.14. Free cash flow of $9.581 billion TTM covers the 2.91% dividend at a 66.5% payout and funded $3.05 billion of Q3 debt repayment, cutting debt-to-equity from 9.24x to 6.31x. Valuation is not stretched on forward numbers — 18.59x forward versus 22.84x trailing earnings, a PEG of 0.259, and EV/EBITDA of 13.11x for a franchise with 62% EBITDA margins — but the 20.3x price-to-book and 7.52x EV/Sales reflect a leveraged, buyback-shrunk equity base rather than cheapness.

The biggest risks that could invalidate the thesis are: (1) margin reversal if Q4 operating margin falls back toward the 31.0% Q1 level as one-off other income fades; (2) Imdelltra launch metrics or MariTide obesity data disappointing against Lilly, Novo Nordisk and Pfizer's berobenatide; and (3) accelerating biosimilar erosion in Aranesp ($329M) and Kyprolis ($330M), plus Tavneos regulatory scrutiny. This Hold would upgrade to Buy if the stock pulls back toward the $431.81 consensus or if Q4 confirms operating margin above 35% without non-operating help; it would downgrade to Sell if operating margin reverts below 32% or if Imdelltra guidance fails to materialize. Verdict: fairly valued to modestly rich relative to consensus targets, but undemanding on forward earnings relative to its own history — a hold, not a chase.

Sign up to view all

AMGN 12-Month Price Forecast

The forward setup is balanced rather than compelling in either direction: fundamentals are improving (8.45% revenue growth, margins inflecting, $9.581 billion free cash flow) and forward valuation at 18.59x is undemanding, but the stock has already re-rated 38.59% over one year and now trades above the average analyst target with a hold consensus. The 25/50/25 probability weighting reflects that the base case of consolidation near $420-450 is most likely, with the margin-recovery durability as the pivotal variable. I would upgrade to bullish if Q4 confirms operating margin above 35% without the other-income assist and Imdelltra launch metrics beat expectations, closing the gap to the $536 high target. I would downgrade to bearish if operating margin reverts below 32% or if biosimilar erosion in Aranesp and Kyprolis accelerates faster than new launches offset it.

Historical Price
Current Price $435.64
Average Target $435.00
High Target $536.00
Low Target $312.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $440.78 and implied upside of +1.2% versus the current price.

Average Target

$440.78

35 analysts

Implied Upside

+1.2%

vs. current price

Analyst Count

35

covering this stock

Price Range

$230 - $550

Analyst target range

Buy
12 (34%)
Hold
18 (51%)
Sell
5 (14%)

Coverage is broad with 29 analysts, but sentiment is decidedly lukewarm: the distribution of 11 Buy, 18 Hold, and 5 Sell produces a consensus recommendation of "hold" and a recommendation mean of 2.71 (where 3.0 is a pure hold), signaling that the sell-side views the recent rally with skepticism. The average target price of $431.81 actually sits 7.3% below the current $465.67 — implying downside to consensus — a notable divergence given the stock's 38.59% one-year gain, suggesting analysts have been slow to mark targets up to the price action rather than the reverse. Recent ratings activity reinforces the cautious tone: Freedom Broker downgraded from Buy to Hold on November 6, while Guggenheim, Leerink, Canaccord, Citigroup, and JPMorgan all maintained Neutral/Hold/Market Perform stances around the November 4 earnings report, with only Argus (Buy), UBS (Buy), Scotiabank (Sector Outperform), and TD Cowen (Buy) staying constructive. The target range is extremely wide — from a low of $230 to a high of $536, a 133% spread — which signals genuine disagreement about the durability of the margin recovery and pipeline value rather than mere noise. The $536 high target implies roughly 15% upside and likely assumes Imdelltra becomes a multi-billion-dollar oncology franchise, MariTide captures meaningful obesity share, and margins hold above 35%, while the $230 low target (a 51% downside) prices in aggressive biosimilar erosion, pipeline disappointment, and leverage-driven risk. That dispersion, combined with a consensus target below spot, means the stock is trading ahead of the Street's published models — a momentum-driven re-rating that will need fundamental confirmation (guidance raises, Imdelltra approval/launch metrics) to close the gap between price and target.

Drowning in data?

Find the real signal!

Bulls vs Bears: AMGN Investment Factors

The bull case currently has stronger near-term evidence: margins inflected decisively in Q3 (73.1% gross, 35.8% operating, 62.3% EBITDA), free cash flow of $9.581 billion comfortably funds the 2.91% dividend and deleveraging, and the 58% mortality-risk reduction for Imdelltra plus Imfinzi is a genuine practice-changing catalyst. The bear case rests less on fundamentals than on positioning: the stock at $465.67 trades 7.3% above the $431.81 consensus target with a "hold" rating and a 133% spread between the $230 low and $536 high targets, meaning price has outrun published models. The single most important tension is whether the margin recovery is structural or aided by one-off other-income swings — Q3's $976 million favorable item versus Q2's -$746 million drag shows how much headline EPS depends on non-operating lines. If Q4 confirms operating-margin expansion above 35% without that help, the multiple can expand toward the $536 bull target; if margins revert toward the 31% Q1 level, the stock is vulnerable to a de-rating toward consensus.

Bullish

  • Margin recovery inflecting sharply: Q3 2026 gross margin expanded to 73.1% from 68.2% in Q1, operating margin rose to 35.8% from 31.0%, and EBITDA margin jumped to 62.3% versus 44.8% in both Q1 and Q2. Net income of $3.864 billion and EPS of $7.14 more than doubled sequentially from Q2's $2.475 billion and $4.40, evidence that Horizon integration and amortization drags are finally rolling off.
  • Forward valuation undemanding for growth: At 18.59x forward earnings versus 22.84x trailing, the market is pricing a 19% EPS compression into the multiple while consensus 2027 EPS sits at $31.15. The PEG ratio of 0.259 is strikingly low for a franchise with 62.3% EBITDA margins and a pipeline catalyst peers lack, leaving room for multiple expansion if guidance rises.
  • Imdelltra data is practice-changing: The Imdelltra plus Imfinzi combination reduced risk of death by 58% in extensive-stage small cell lung cancer, per the November 2 news flow. That is a potential multi-billion-dollar oncology franchise that would diversify Amgen away from its eroding legacy hematology support products.
  • Idiosyncratic momentum leadership: The stock is up 38.59% over one year and 42.13% YTD, outperforming the S&P 500 by 26.32 and 31.51 percentage points respectively, with relative strength of +11.54 over one month while the index fell 2.26%. Beta of just 0.417 and a max drawdown of only -16.57% mean this re-rating came from stock-specific demand, not market beta.

Bearish

  • Consensus target sits below spot: The $431.81 average analyst target is 7.3% below the current $465.67, and the consensus recommendation is "hold" with a mean of 2.71 across 29 analysts (11 Buy, 18 Hold, 5 Sell). The stock is trading ahead of the Street's published models, a momentum re-rating that needs fundamental confirmation to close the gap.
  • Extreme target dispersion signals disagreement: Targets range from $230 to $536, a 133% spread, with the low end implying 51% downside. That dispersion reflects genuine disagreement about the durability of margin recovery and pipeline value, not noise, and Freedom Broker's November 6 downgrade from Buy to Hold reinforces the cautious tone.
  • Leverage constrains financial flexibility: Debt-to-equity of 6.31x from the Horizon deal leaves a current ratio of just 1.14, with $13.19 billion of cash against $653 million of quarterly interest expense. Price-to-book of 20.3x reflects a buyback-shrunk, leveraged equity base rather than operational richness, and financial flexibility is thinner than large-cap pharma peers.
  • Earnings sensitive to non-operating swings: Q3's $976 million favorable other-income swing versus Q2's -$746 million other-expense drag drove much of the sequential EPS jump, meaning headline profitability is not purely operational. Q4 2025 already showed how quickly this reverses, with other expenses of -$2.428 billion collapsing EPS to $2.47.

AMGN Technical Analysis

Amgen is in a powerful, sustained uptrend: the stock is up 38.59% over the past year and 42.13% year-to-date, and at $465.67 it trades at roughly 89% of its 52-week range (low $312.39, high $483.99), just 3.8% below the high. That positioning signals momentum leadership rather than overextension, particularly given the stock has outperformed the S&P 500 by 26.32 percentage points over one year and 31.51 points YTD. The 52-week range itself is wide at $171.60, reflecting a full trend reversal from the late-2025/early-2026 base near $312 into a durable advance. Recent momentum confirms acceleration rather than decay: the stock is up 9.28% in the past month and 12.15% over three months, with the one-month gain outpacing the three-month gain on an annualized basis and the six-month change at a striking 42.71%. Critically, this strength is occurring against a weak tape — the S&P 500 is down 2.26% over one month and 2.83% over three months — producing relative strength of +11.54 (1M) and +14.98 (3M), evidence of genuine idiosyncratic demand rather than beta-driven drift. The lone caution flag is the most recent session's -0.30% slip from a $478.48 intra-period peak on November 4, suggesting some profit-taking near highs. Key resistance sits at the $483.99 52-week high; a decisive breakout would likely require confirmation from the Imdelltra oncology data and MariTide narrative and could open a new leg higher, while support is anchored at the $312.39 52-week low with intermediate support around the $440-450 shelf that contained the September pullback. Volatility is remarkably contained for a single-name biotech: beta of just 0.417 implies roughly 58% less volatility than the S&P 500, and a max drawdown of only -16.57% over the period underscores defensive characteristics that support larger position sizing, though the low beta also means the stock's 38.59% one-year gain was driven by stock-specific re-rating rather than market tailwinds.

Beta

0.42

0.42x market volatility

Max Drawdown

-16.6%

Largest decline past year

52-Week Range

$312-$484

Price range past year

Annual Return

+29.6%

Cumulative gain past year

PeriodAMGN ReturnS&P 500
1m-0.6%-9.7%
3m-0.8%-9.9%
6m+28.4%-7.5%
1y+29.6%+4.7%
ytd+33.0%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

AMGN Fundamental Analysis

Revenue is growing at a healthy clip: Q3 2026 revenue of $10.365 billion rose 8.45% year-over-year versus $9.557 billion in Q3 2025, and the sequential trajectory ($8.618B in Q1, $10.054B in Q2, $10.365B in Q3) shows steady expansion through 2026 after a lumpy 2025. The product mix reveals the growth engine: Repatha at $1.085 billion and Evenity at $751 million lead the portfolio, with Prolia ($632M), Enbrel ($611M), Tezspire ($538M), Tepezza ($526M), and Blincyto ($496M) providing diversification, while legacy Aranesp ($329M) and Kyprolis ($330M) face biosimilar and competitive pressure. The 8.45% growth rate, against consensus full-year revenue estimates of $47.31 billion, implies the company is on track for mid-to-high single-digit expansion — respectable for a mature biotech but dependent on new launches like Imdelltra offsetting erosion in the base. Profitability has inflected sharply: Q3 2026 net income of $3.864 billion produced a 37.3% net margin and EPS of $7.14, up dramatically from $2.475 billion and $4.40 in Q2, while gross margin expanded to 73.1% from 68.2% in Q1 and 72.0% in Q2. Operating margin reached 35.8% in Q3 versus 31.0% in Q1, and the Q3 EBITDA margin of 62.3% (versus 44.8% in Q2 and 44.8% in Q1) reflects both operating leverage and a favorable $976 million swing in other income — though investors should note the Q2 other-expense drag of -$746 million shows earnings remain sensitive to non-operating items. The balance sheet is the key watch item: debt-to-equity of 6.31x (down from 9.24x in Q1 2025) reflects the Horizon-funded leverage, and with a current ratio of just 1.14 and cash of $13.19 billion against heavy debt service, financial flexibility is thinner than peers. Still, free cash flow is robust at $9.581 billion TTM and $3.654 billion in Q3 alone, comfortably covering $1.363 billion in quarterly dividends (payout ratio 66.5%) and $3.05 billion of Q3 debt repayment; ROE of 89.1% is inflated by the thin equity base but confirms strong capital returns, while ROA of 8.91% is solid for the sector.

Quarterly Revenue

$10.4B

2026-09

Revenue YoY Growth

+8.5%

YoY Comparison

Gross Margin

73.1%

Latest Quarter

Free Cash Flow

$9.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Aranesp
BLINCYTO
ENBREL
EVENITY
KRYSTEXXA
Kyprolis
Nplate
Otezla
Other Products
Product and Service, Other
Prolia
Repatha (evolocumab)
TEPEZZA
TEZSPIRE
Vectibix
XGEVA

Open an Account, get $2 TSLA now!

Valuation Analysis: Is AMGN Overvalued?

Because Amgen is solidly profitable (Q3 net income of $3.864 billion, TTM EPS positive), the PE ratio is the appropriate primary metric: the stock trades at 22.84x trailing earnings but only 18.59x forward earnings, a 19% compression that implies the market expects meaningful EPS growth — consistent with consensus 2027 EPS estimates of $31.15 versus the current run-rate. The forward multiple of 18.6x on a business growing revenue 8.45% and expanding margins is undemanding in absolute terms, and the PEG ratio of 0.259 is strikingly low, suggesting the market is not paying up for that growth. Relative to the Drug Manufacturers - General industry, Amgen screens as a modest premium on some measures and a discount on others: its PS ratio of 4.79x and EV/Sales of 7.52x are elevated versus big-pharma norms, but its PE of 22.8x trailing/18.6x forward sits at or below the sector's typical high-teens-to-low-20s range, and its 2.91% dividend yield plus 70.8% gross margin and 29.1% operating margin are competitive with large-cap pharma peers. The premium embedded in EV/EBITDA of 13.11x is reasonable for a franchise with 62% EBITDA margins and a pipeline catalyst (Imdelltra, MariTide) that peers lack, though the 20.3x price-to-book reflects the leveraged, buyback-shrunk equity base rather than operational richness. Historically, Amgen's PE has ranged widely — from 11.8x in Q3 2025 and 14.8x in Q3 2026's reported quarter to 33.1x in Q4 2025 and 55.7x in Q4 2024 during earnings troughs — so the current 22.8x trailing sits in the middle of its multi-year band, neither cheap nor stretched. The more telling signal is the forward PE of 18.6x against a historical median in the low-20s, implying the market is pricing in margin recovery but not yet fully capitalizing the oncology and obesity pipeline optionality — a setup that leaves room for multiple expansion if Imdelltra data converts into guidance raises.

PE

22.8x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 11x~33x

vs. Industry Avg

18.6x

Industry PE ~18.6x*

EV/EBITDA

13.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on leverage and earnings quality. Debt-to-equity of 6.31x from the Horizon acquisition, a current ratio of just 1.14, and $653 million of quarterly interest expense leave limited flexibility, while Q3's 37.3% net margin was flattered by a $976 million favorable other-income swing that followed a -$746 million drag in Q2 and a -$2.428 billion hit in Q4 2025. Revenue concentration in mature franchises is a further vulnerability: Aranesp ($329M) and Kyprolis ($330M) face biosimilar and competitive erosion, and the 8.45% YoY growth to $10.365 billion depends on new launches like Imdelltra and Repatha ($1.085 billion) offsetting that decay. Finally, the 66.5% payout ratio on $1.363 billion of quarterly dividends means capital returns compete directly with debt service for the $3.654 billion of quarterly free cash flow.

Market and competitive risks are dominated by valuation and positioning. At 22.84x trailing and 18.59x forward earnings the multiple sits mid-range historically, but price-to-book of 20.3x and EV/Sales of 7.52x are elevated versus big-pharma norms, and the stock trades 7.3% above the $431.81 consensus target with 18 of 29 analysts at Hold. Beta of 0.417 means macro rotation is a modest risk, but the stock's 38.59% one-year gain was driven by idiosyncratic re-rating, so any loss of that specific demand leaves little market tailwind to cushion a pullback. Competitive threats are real: MariTide's once-monthly dosing must carve share against Lilly and Novo Nordisk, Pfizer's berobenatide adds another obesity entrant, and Tavneos faces global regulatory scrutiny for data manipulation and safety concerns that could damage partner relationships and reputation.

The worst-case scenario is a margin-recovery reversal combined with pipeline disappointment. If Q4 operating margin reverts toward the 31.0% Q1 level as one-off other income fades, Imdelltra launch metrics underwhelm, and biosimilar erosion accelerates in Aranesp and Kyprolis, the stock would de-rate toward the $431.81 consensus and then the $230 low target. From $465.67, a move to the 52-week low of $312.39 represents roughly -33%, and a full repricing to the $230 bear target would be about -51%. The historical max drawdown of only -16.57% understates this risk because it was measured during a strong uptrend; the September 8 gap from $437.23 to $393.17 (-10% in a single session) shows how quickly sentiment can shift when price is extended 3.8% below the $483.99 high.

FAQ

Ranked by severity: first, earnings-quality and margin-reversal risk — Q3's 37.3% net margin was flattered by a $976 million favorable other-income swing after a -$746 million Q2 drag and a -$2.428 billion Q4 2025 hit, so a reversion toward the 31.0% Q1 operating margin would undercut the recovery thesis. Second, balance-sheet and leverage risk — debt-to-equity of 6.31x from the Horizon deal, a current ratio of just 1.14, and $653 million of quarterly interest expense leave limited flexibility, with the 66.5% dividend payout competing with debt service for cash. Third, competitive and pipeline risk — MariTide must carve obesity share against Lilly, Novo Nordisk, and Pfizer's berobenatide, while Imdelltra launch metrics must materialize to offset biosimilar erosion in Aranesp ($329M) and Kyprolis ($330M). Fourth, company-specific and regulatory risk — Tavneos faces global scrutiny for data manipulation and safety concerns, and the 133% analyst target spread ($230 to $536) signals genuine disagreement about the durability of the story.

The 12-month forecast is weighted 50% base, 25% bull, and 25% bear. The base case (50% probability) targets $420-450, assuming roughly 8% revenue growth toward the $47.31 billion consensus, operating margin holding at 33-36%, and the stock consolidating near the $431.81 average target at 18-19x forward earnings. The bull case (25%) targets $510-536, requiring Imdelltra to convert its 58% mortality-risk reduction into a multi-billion-dollar franchise, MariTide to secure obesity share, and Q4 to confirm operating margin above 35% without other-income help, driving multiple expansion toward the $536 high target. The bear case (25%) targets $312-350, driven by margin reversion toward 31%, disappointing Imdelltra launch metrics, accelerated biosimilar erosion, and Tavneos scrutiny, with the $230 low target as the tail scenario. The base case is most likely, and its key assumption is that the Q3 margin inflection proves structural rather than aided by one-off items.

The valuation is mixed depending on the metric: at 22.84x trailing and 18.59x forward earnings, AMGN sits mid-range of its own multi-year PE band (which has ranged from 11.8x in Q3 2025 to 55.7x in Q4 2024 during earnings troughs) and at or below the typical high-teens-to-low-20s range for large-cap pharma, suggesting it is not expensive on earnings. The forward multiple implies the market expects roughly 19% EPS growth, consistent with consensus 2027 EPS of $31.15, and the 0.259 PEG is strikingly low for a franchise with 62.3% EBITDA margins. However, price-to-book of 20.3x and EV/Sales of 7.52x look rich versus big-pharma norms, though these reflect a leveraged, buyback-shrunk equity base (debt-to-equity 6.31x) rather than operational excess. Relative to the Street, the stock is modestly overvalued — trading 7.3% above the $431.81 consensus target — so the market is pricing in margin recovery and some pipeline optionality but not fully capitalizing Imdelltra or MariTide. Net verdict: fairly valued to modestly rich versus consensus, undemanding versus its own history.

From a risk/reward standpoint, AMGN is a reasonable hold but a less attractive fresh buy at $465.67, because the price already sits 7.3% above the $431.81 average analyst target and the consensus is "hold" (mean 2.71 across 29 analysts: 11 Buy, 18 Hold, 5 Sell). The upside case is real — the $536 high target implies roughly 15% upside if Imdelltra and MariTide deliver and margins hold above 35% — but the downside to the $312.39 52-week low is about -33%, and the $230 low target implies -51%, so the reward-to-risk is roughly balanced rather than skewed favorably. Fundamentals support patience: 8.45% revenue growth, 73.1% gross margin, $9.581 billion TTM free cash flow, and an 18.59x forward multiple with a 0.259 PEG. It is a good buy primarily for income-oriented, low-volatility investors (2.91% yield, beta 0.417) willing to accumulate on pullbacks toward the $431.81 consensus, and less so for investors chasing the 38.59% one-year move at current levels.

AMGN is better suited to long-term holding than short-term trading. It is a mature, cash-generative biotech with 8.45% revenue growth, $9.581 billion TTM free cash flow, a 2.91% dividend at a 66.5% payout, and a beta of just 0.417, which supports a lower-volatility, income-plus-growth role in a portfolio rather than tactical trading. The stock's 38.59% one-year and 42.13% YTD gains have already captured much of the near-term re-rating, and with price 7.3% above the $431.81 consensus target, short-term upside is limited and the September 8 single-session drop from $437.23 to $393.17 (-10%) shows how quickly sentiment can reverse near highs. Earnings visibility is moderate — headline EPS swings with non-operating items — so a suggested minimum holding period of 18-24 months allows time for the margin recovery to be confirmed across Q4 2026 and Q1 2027 and for Imdelltra and MariTide data to mature. Short-term traders should wait for a pullback toward the $431.81 consensus or a confirmed breakout above the $483.99 52-week high before entering.